Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- LIV LABS INC
- Proposal award date
- 2021-04-09
- Contract end date
- 2023-03-31
- UEI
- XBM9L92LT4D1
- Solicitation number
- PA20-262
- Topic code
- NICHD
Research abstract
Project Summary/Abstract
Liv Labs has developed a novel, reusable, self-administered silicone pessary for patient-controlled treatment of
female stress urinary incontinence (SUI), a bothersome condition that affects some 27 million American women
over the age of 25. Unlike the fitted and disposable pessaries available on the market today, this patent-
pending Soft Spring Continence Pessary is a symmetrical, hollow, resilient form placed above the pelvic floor—
not to kink the urethra, as other effective devices and surgical procedures do, but rather to gently compress the
urethra through soft, vaginal tissue. The device compresses down into a 10mm cylinder for applicator-assisted
insertion and features an integrated finger loop for easy manual removal. Comprising only soft, rounded
surfaces, the spring pessary can be lubricated and is intended for patients with vaginal atrophy who sometimes
experience pain, lacerations, or injury with existing devices. The Liv Labs team has already completed bench
testing, focus groups, caregiver assessments, design review with clinicians, and a two-week, IRB-approved,
pilot feasibility study with nine symptomatic women. Directional efficacy and safety were reported, as well as
high user satisfaction. During Phase II, Liv Labs will ensure the pessary meets all requirements for pre-clinical
design validation. Output will include engineering specifications and drawings; quality system framework; risk
assessment; and results for biocompatibility, toxicity, and forces testing. First a controlled, single-use human
factors study will be held to confirm safe and accurate device use (Aim 1). Then a single-arm, open label,
interventional efficacy study will be conducted at Northwestern University’s Integrated Pelvic Health Program
Clinic (Aim 2). The study will enroll 50 women diagnosed with SUI by means of an in-clinic Cough Stress Test.
Enrolled patients will participate in an 17-day pad weight test, to confirm device efficacy. Upon completion of
evaluative questionnaires, the same participants will then immediately enter a prospective, descriptive study of
patient-managed device use for a period of six months (Aim 3). The team at Liv Labs comprises late-career
product developers with experience inventing medical devices and software, branded consumer products and
services, and technology-enabled, proactive care models for aging in place. The team is closely advised by a
panel of practicing urogynecologists and OB/GYNs. The extended development team has collaborated closely
with Liv Labs for three years and includes top-tier consultants in engineering, manufacturing, quality systems,
clinical testing and regulatory strategy. Once commercialized, the first-ever Soft Spring Continence Pessary will
provide millions of women, from all walks of life, a practical, affordable way to self-treat their SUI symptoms
and increase their inclination toward fitness.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
3 SBIR/STTR records share this UEI (2021–2024). Reported award amounts total $2,492,073. Reported amounts are not federal obligations.
Phases: Phase II, Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, National Science Foundation
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards